Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Return on Capital Employed of 21.85% for Q1 2026, up 944.0% year-over-year from 2.09% in Q1 2025, and up 16.23% quarter-over-quarter from 26.09% in Q4 2025.
Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Return on Capital Employed for 7 consecutive years, with 21.85% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 944.0% year-over-year to 21.85%; the TTM figure through Mar 2026 stood at 21.85% (up 944.0% YoY), while the FY2025 annual figure was 27.36%, up 954.0% from the prior year.
- Return on Capital Employed improved to 21.85% in Q1 2026 per KYMR's latest filing, from 26.09% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.85% in Q1 2026 and bottomed at 36.68% in Q3 2023.
- Historically, Return on Capital Employed has averaged 29.23% across 5 years, with a median of 30.8% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 1411 bps — and 2024, when it soared 1350 bps.
- Kymera Therapeutics' Return on Capital Employed stood at 29.35% in 2022, then slipped by 18 bps to 34.6% in 2023, then advanced by 19 bps to 27.87% in 2024, then gained by 6 bps to 26.09% in 2025, then grew by 16 bps to 21.85% in 2026.
- Business Quant data shows KYMR's Return on Capital Employed at 21.85% in Q1 2026, 26.09% in Q4 2025, and 31.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -22.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.08% |
| Mar 31, 2026 | -21.85% |
| Dec 31, 2025 | -26.09% |
| Sep 30, 2025 | -31.80% |
| Jun 30, 2025 | -33.28% |
| Mar 31, 2025 | -31.29% |
| Dec 31, 2024 | -27.87% |
| Sep 30, 2024 | -23.17% |
| Jun 30, 2024 | -23.64% |
| Mar 31, 2024 | -26.74% |
| Dec 31, 2023 | -34.60% |
| Sep 30, 2023 | -36.68% |
| Jun 30, 2023 | -31.70% |
| Mar 31, 2023 | -31.04% |
| Dec 31, 2022 | -29.35% |
| Sep 30, 2022 | -31.97% |
| Jun 30, 2022 | -30.80% |
| Mar 31, 2022 | -25.05% |
| Dec 31, 2021 | -18.91% |
| Sep 30, 2021 | -17.87% |